
Much patent discourse during the last decade has been driven by the perceived vulnerability of manufacturers to patent assertion by so-called “non-practicing entities,” known as NPEs (or less charitable epithets), who own patents but do not practice them. A Pricewaterhouse Coopers 1995-2009 patent litigation study, The Continued Evolution of Patent Damages Law, puts the fraction of decided patent cases involving NPEs over that period at 19.4%.
While the merits of a patent suit might be considered to rest on the simple question of whether a party is infringing a valid patent, part of the disquietude with NPE suits derives from the perception that NPEs have nothing to lose because they are not in a business covered by the patents at suit.
The Federal Circuit’s recent decision, in MarcTec, LLC v. Johnson & Johnson and Cordis Corporation, is likely to change that perception. It affirms a federal trial court’s judgment against an NPE and an award of $4.9 million to cover the attorneys’ fees and expert costs incurred by the defendants.
The two patents asserted by plaintiff MarcTec are drawn from a portfolio of over 219 U.S. and foreign patents and 143 pending patent applications held by MarcTec, many of which are listed on the curriculum vitae of Dr. Peter Bonutti, an Effingham, Illinois orthopedic surgeon and (obviously) a prolific inventor.
The two patents, differing in claims but otherwise identical, are drawn to a “tubular member” (or a “surgical device”) that is implantable in the body, is expandable and has a polymer containing a therapeutic agent bonded to it. One might be excused for thinking that this sounds like the description of a drug-eluting stent (or “intraluminal graft,” as it is called in the art).[Read the full article]


